Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Nov;14(6):805-6.
doi: 10.1038/aja.2012.113. Epub 2012 Oct 8.

Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer

Jeanny B Aragon-Ching  1
Affiliations
Comment

Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer

Jeanny B Aragon-Ching. Asian J Androl. 2012 Nov.

Abstract

Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate cancer (mCRPC). AFFIRMwas a phase III international randomized trial that evaluated the clinical utility of enzalutamide versus placebo in men with mCRPC who have failed prior docetaxel-containing chemotherapy. Enzalutamide showed a remarkable 37% decreased risk of death with a median overall survival of 18.4 months versus 13.6 months for those who received placebo. These findings confirm the validity of further targeting the androgen receptor as a valid therapeutic approach in prostate cancer despite emergence of castration resistance.

PubMed Disclaimer

Comment on

  • Increased survival with enzalutamide in prostate cancer after chemotherapy.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Clinical Trial.

References

    1. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46. - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 20123671187–97.Epub 2012 Aug 15. - PubMed
    1. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007;13:2030–7. - PubMed
    1. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72:2176–82. - PMC - PubMed
    1. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). (accessed 19 August 2012). http://clinicaltrials.gov/ct2/show/study/NCT01212991?show_locs=Y#locn.